PE-22-28 Alternatives

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.

A synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.

A mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.

A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.

A synthetic peptide mimetic of CNTF (ciliary neurotrophic factor) designed for neurodegenerative disease. Promotes neurogenesis and reduces neuroinflammation.

A dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.

An 11-amino acid peptide derived from erythropoietin (EPO) that activates the innate repair receptor. Unlike EPO, it has no erythropoietic activity but provides cytoprotective, anti-inflammatory, and tissue-protective effects.

A synthesized Khavinson peptide bioregulator containing short peptides (2-4 amino acids) derived from retinal tissue. Developed to normalize retinal function and support eye health. Clinical studies in Russia report improved visual function in 95% of patients with various retinal pathologies.